Rohtak News Magazine

AVCO could be the Next Big Biotech on the NASDAQ Roundtable as JAZZ signs Licensing Agreement with HOWL

 Breaking News
  • No posts were found

AVCO could be the Next Big Biotech on the NASDAQ Roundtable as JAZZ signs Licensing Agreement with HOWL

April 18
08:20 2022
$AVCO a Leading global developer of cell-based Technologies & Therapeutics could be the next big biotech on the NASDAQ roundtable.

Werewolf Therapeutics Inc. $HOWL shares rose 26% Thursday after the company signed a licensing agreement with Jazz Pharmaceuticals PLC $JAZZ worth up to $1.2 billion.. The companies said they entered an exclusive global license and collaboration agreement to develop WTX-613, a preclinical immuno-oncology candidate. Werewolf said WTX-613 exhibited robust anti-tumor activity in preclinical studies.

$HOWL will receive a $15 million upfront payment, with the potential to receive up to $1.26 billion in various payments as well as royalties on future net sales, the companies said. At 11:44 a.m. ET, Werewolf’s shares were up 26% at $5.96. Volume at the time topped 9.4 million shares, above the stock’s 65-day average volume of 70,466.

$JAZZ said it expects to submit an investigational new drug application to the U.S. Food and Drug Administration for WTX-613 next year.

AVCO offers Life Saving Medical Advances; AI & Immunotherapy for Cancer & Immune-Related Diseases Including COVID-19 (Early-Stage): Avalon GloboCare Corp. (NASDAQ: AVCO)

– Clinical-Stage CellTech Developer Dedicated to Immune Effector Cell Therapy and Exosome Technology.

– Introducing Life Saving COVID-19 Diagnostics and Therapeutics.

– New Treatment for Deadly Cytokine Storm in COVID-19 Patients.

– Novel Technology to Efficiently Synthesize & Study Previously Difficult to Work With Drug Targets.

– Technology Will Facilitate Drug Design for Cancer & Immune Diseases.

– Study Published in September 2021 Issue of Journal Membranes.

– Leveraging Avalon’s existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeutics

– Clinical development of CAR-NK cell therapy planned in collaboration with the Company’s clinical partner, Lu Daopei Hospital, as a potential treatment for hematologic malignancies and other unmet medical areas

– Appoints Dongfang Liu, Ph.D., a world-class scientist and expert in CAR-NK technology, to Avalon’s Scientific and Clinical Advisory Board

– Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients

Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in patients suffering from COVID-19. The condition is an inflammatory syndrome triggered by hyperactivation of immune cells that can significantly impact the patient’s chances of making a full recovery or surviving the infection at all.

Fortunately, AVCO has already been developing a range of therapies that have the potential to help target cytokine storm and other risk factors that make the widespread virus so difficult to get under control.

What Is Cytokine Storm?

The immune system uses cytokines to perform a variety of important tasks from clotting blood to triggering antibody production. When overworked — as can happen when the body is fighting off an aggressive, difficult disease like COVID-19 or is being treated with therapies designed to activate an immune response — that same immune system can end up producing too many cytokines. When the ones that trigger an inflammatory response are produced in excess, the cytokines trigger severe inflammatory symptoms, damage healthy tissue, and can even cause multiple organs to fail, leading to death.

AVCO AVA-Trap™ Already Targets Cytokine Storm.

Because cytokine storm is a common risk factor in many cancer therapies, the oncology-focused AVCO was already hard at work on a way to calm down cytokine storms. The AVCO AVA-Trap™ therapeutic program was developed to target this potentially fatal complication. By using cytokine receptor proteins, the AVA-Trap™ program could dampen the release of cytokine, essentially filtering out the excess cytokines.

When COVID-19 started to spread through populations around the globe in 2020, doctors soon realized that the virus could induce a cytokine storm and that, when it did, the chances of that patient surviving grew slim. AVCO moved quickly to file and expanded patent for the proprietary filtration technology so it could be used to help COVID patients increase their chances of recovering from the disease.

For more information on Avalon GloboCare Corp. (NASDAQ: AVCO) visit:

DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way to buying or selling stocks.

Media Contact
Contact Person: Support
Email: Send Email
Phone: 732-780-4400
Country: United States

Related Articles